The results of our study, conducted on a large cohort of “real life” women over 50 years of age on adjuvant hormone therapy for breast cancer, indicate that, compared to tamoxifen, aromatase inhibitors increase the risk of CV events and, in particular, heart failure. Here, CYP19A1 is linked to breast carcinoma.